Loading
A phase 1/2 trial of GFH375, Cetuximab, Paclitaxel / nab-paclitaxel in colorectal cancer, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation is a phase 1/2 interventional study registered as NCT07259590 by Genfleet Therapeutics (Shanghai) Inc., with 126 participants planned, started 2025-10-21 and due to reach its primary completion in 2027-07. Interventions recorded: GFH375, GFH375. Conditions listed: Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer). No results are recorded here; the registry entry is the source.
Shares GFH375, GenFleet Therapeutics.
Shares GFH375, GenFleet Therapeutics.
Shares KRAS G12C-mutant colorectal cancer, Cetuximab, Monoclonal antibodies, Colorectal cancer.
Shares GFH375, GenFleet Therapeutics.
Shares Cetuximab, Paclitaxel / nab-paclitaxel, Gemcitabine, Colorectal cancer.
Shares GFH375, GenFleet Therapeutics.
Shares KRAS G12C-mutant colorectal cancer, Cetuximab, Monoclonal antibodies, Colorectal cancer.
Shares GenFleet Therapeutics, Colorectal cancer.